26+ years of experience
Rachel began her time at Citeline as a drug specialist, managing Trialtrove’s auxiliary drug database. Since then, she has worked as an analyst specializing in autoimmune/inflammation drugs, immuno-oncology/immunotherapy, pharmacogenomic biomarkers, companion diagnostics, repurposing of drugs and regulatory approval pathways.
Before joining us, Rachel was a scientist in genetic and molecular toxicology for a global contract research organization. She also worked as an adjunct professor at two community colleges and as a research fellow in vascular biology, pharmacology and cancer biology.
By Rachel Meighan-Mantha 22 Mar 2017
The field of epigenetics is rapidly expanding and as interest continues to grow, epigenetics has become an increasingly promising area for research.
By Rachel Meighan-Mantha 21 Jul 2016
Plenty of excitement has been generated recently in the immuno-oncology sphere by the accelerated approvals in May 2016 by the FDA for Bristol-Myers Squibb’s PD-1 antagonist, nivolumab (Opdivo), in relapsed/refractory classical Hodgkin’s lymphoma and for Genentech’s PD-L1 antagonist, atezolizumab (Tecentriq), in relapsed/refractory, advanced or metastatic urothelial carcinoma.
Rachel Meighan-Mantha 09 Apr 2016
In my previous blog, I reported on my analysis of outcomes and endpoints by disease for the top five Asian cancers. For the final blog in this series.
By Rachel Meighan-Mantha 01 Sep 2014
According to GLOBOCAN 2012, the top five cancers in all Asian countries for both genders in terms of age-standardized rates of incidence and mortality are: Lung, including both non-small cell and small cell, Stomach (Gastric), Breast, Colorectal and Liver.
Topic Clinical Trials